T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Crown Castle
CCI
$31.3B
| $2.72B | 0.59% |
36,678,032
-5,773,911
| -14% | -$433M |
|
27
Johnson & Johnson
JNJ
$631B
| $2.72B | 0.59% |
26,004,474
+51,819
| +0.2% | +$5.24M |
|
|
ALXN
28
DELISTED
Alexion Pharmaceuticals
ALXN
| $2.7B | 0.58% |
17,303,461
+1,829,752
| +12% | +$289M |
|
|
AGN
29
DELISTED
Allergan Inc
AGN
| $2.69B | 0.58% |
15,919,404
+8,326,553
| +110% | +$1.3B |
|
30
Merck
MRK
$323B
| $2.63B | 0.57% |
47,711,882
+383,570
| +0.8% | +$20.9M |
|
31
Thermo Fisher Scientific
TMO
$222B
| $2.54B | 0.55% |
21,539,155
+2,060,498
| +11% | +$243M |
|
|
MRSH
32
Marsh
MRSH
$91B
| $2.54B | 0.55% |
48,990,485
-1,245,442
| -2% | -$61.9M |
|
33
Range Resources
RRC
$9.41B
| $2.52B | 0.55% |
29,031,513
+559,052
| +2% | +$50M |
|
|
AMTD
34
DELISTED
TD Ameritrade Holding Corp
AMTD
| $2.49B | 0.54% |
79,537,584
-1,555,836
| -2% | -$48.2M |
|
35
Pfizer
PFE
$154B
| $2.48B | 0.54% |
88,229,707
-22,501,805
| -20% | -$641M |
|
36
Starbucks
SBUX
$119B
| $2.48B | 0.54% |
64,087,716
+778,550
| +1% | +$28.3M |
|
37
APA Corp
APA
$14.4B
| $2.38B | 0.51% |
23,670,691
+670,477
| +3% | +$60.7M |
|
|
38
Morgan Stanley
MS
$338B
| $2.35B | 0.51% |
72,810,853
+22,086,294
| +44% | +$681M |
|
39
Sherwin-Williams
SHW
$88.1B
| $2.34B | 0.51% |
33,959,457
+3,327,039
| +11% | +$222M |
|
40
State Street
STT
$51.3B
| $2.31B | 0.5% |
34,372,252
-207,200
| -0.6% | -$13.6M |
|
|
CELG
41
DELISTED
Celgene Corp
CELG
| $2.29B | 0.49% |
26,649,341
+251,673
| +1% | +$19.1M |
|
42
American Express
AXP
$229B
| $2.28B | 0.49% |
24,051,896
-512,695
| -2% | -$46.2M |
|
43
Microsoft
MSFT
$3.76T
| $2.26B | 0.49% |
54,275,235
-5,981,574
| -10% | -$242M |
|
44
Chevron
CVX
$382B
| $2.26B | 0.49% |
17,329,464
-827,536
| -5% | -$103M |
|
45
Ecolab
ECL
$79.7B
| $2.26B | 0.49% |
20,256,912
-451,593
| -2% | -$48.4M |
|
46
Bank of America
BAC
$447B
| $2.23B | 0.48% |
145,149,433
+8,462,679
| +6% | +$131M |
|
47
Las Vegas Sands
LVS
$29.4B
| $2.17B | 0.47% |
28,471,192
-351,458
| -1% | -$26.7M |
|
48
Netflix
NFLX
$318B
| $2.16B | 0.47% |
343,102,830
+28,817,740
| +9% | +$156M |
|
|
49
Wynn Resorts
WYNN
$10.6B
| $2.1B | 0.45% |
10,095,626
+3,002,433
| +42% | +$622M |
|
50
Chipotle Mexican Grill
CMG
$40.7B
| $2.09B | 0.45% |
176,267,450
-3,127,950
| -2% | -$33.9M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.